Clinical Trials Browser

Metastatic Squamous Non-Small Cell Lung Carcinoma

NCT01639508 2025-12-17

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Phase 2 Recruiting

86 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05859217 2024-05-08

Cabatezo-1

Phase 2 Not yet recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Phase 2 Completed

100 enrolled 14 charts

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT04173338 2022-06-14

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Phase 1 Terminated

9 enrolled

GenitourinaryOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT02132598 2021-03-10

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Phase 2 Terminated

5 enrolled 18 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT01588821 2020-09-29

Cabozantinib in Advanced Solid Malignancies

Phase 2 Completed

37 enrolled 10 charts

GenitourinaryThoracic

Lung Neoplasms, Neoplasm Metastasis, Prostatic Neoplasms, Recurrence

NCT03911193 2019-04-11

CABinMET

Phase 2 Unknown

25 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

LUNG-IST-127

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Cabatezo-1

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma

Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases

Cabozantinib in Advanced Solid Malignancies

CABinMET